Impact of the M22-IPL Acne Filter on Acne Vulgaris

Not Applicable

Terminated

• Conditions: Acne
• Interventions: Device: M22-IPL

• Registration Number: NCT02180282
• Lead Sponsor: Lumenis Be Ltd.

Brief Summary

Up to 20 healthy subjects age 15-45 years old ,Skin Phototype I-V,Study will be conducted in 1 site.

Primary objectives is to evaluate the efficacy of IPL acne filter treatment for improvement of acne vulgaris as assessed by lesion count.

.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-07
• Study First Submitted: 2014-07-01
• Study First Submitted QC: 2014-07-01
• Study First Posted: 2014-07-02
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-25
• Last Update Posted: 2017-01-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

1. Able to read, understand and provide written Informed Consent;
2. Healthy male or female, 15-45 years of age;
3. Fitzpatrick skin type I-V;
4. Have at least 15 inflammatory lesions (papules and pustules) in the face.
5. Having clinical diagnosis of mild to moderate inflammatory acne on face with Investigator Global Acne scale = 2 and 3;
6. Able and willing to comply with the treatment/follow-up schedule and requirements;
7. Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, and partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.

Exclusion Criteria

1. Skin type VI;
2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding;
3. Heavy smoker (>1 pack of cigarettes a day);
4. Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study;
5. Photosensitivity or any sensitivity to the sun that causes a rash or allergic reaction;
6. Use of photosensitive medication for which light exposure is contraindicated;
7. Treatment with topical retinoid therapy or antibiotics for the treatment of acne within 2 weeks of study enrollment or during the study.
8. Treatment with oral retinoid medications (Accutane® or Soriatane®) within 6 months of the study enrollment or during the study.
9. Treatment with any topical or systemic anti acne therapy for at least 2 weeks prior to starting the study treatment or during the study.
10. Any history of gold therapy;
11. Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants;
12. Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study;
13. Any other surgery in treated area within 9 months of initial treatment or during the course of the study;
14. Participation in a study of another investigational device or drug involving the same anatomical site within 3 month prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion;
15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area;
16. Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma);
17. Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on area to be treated during the course of treatment;
18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;
19. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion);
20. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications;
21. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face;
22. Mentally incompetent or evidence of active substance or alcohol abuse;
23. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study;
24. For subjects undergoing test spots: considerable undesired response consisting of skin hypopigmentation (long term whitening), a scar or pre scar formation or any response deemed by the Investigator as grounds for exclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Acne Treatment	M22-IPL	Acne treatment using the M22-IPL acne filter

Primary Outcome Measures

Name	Time	Method
lesion count of acne vulgaris will be reduced by at least 50% for >75% of the study population.	week 6 (week 1 after the last treatment)	The numbers of lesions are counted on each side of the face according to lesion type

Secondary Outcome Measures

Name	Time	Method
The Cardiff Acne Disability Index	Baseline ,4,6,10 weeks	The Cardiff Acne Disability Index is a short 5 item questionnaire derived from the longer Acne Disability Index
Long term side effect and adverse events	throughout the duration of the study (Baseline,2,3,4,5 weeks)	Any adverse events associated with various setting used during the treatment and follow-up period
Subject Downtime Evaluation	Following treatments baseline,2,3,4,5 weeks	The downtime will be defined as the period of time following the procedure during which the subject had edema and erythema and felt unable/unwilling to go out in public
Investigator Global Assessment (IGA) Scale for Acne Vulgaris	following the treatments: at Baseline ,5 weeks and at follow up 6 and 10 weeks.	The investigator will be required to grade the acne severity using the IGA scale
Subject Satisfaction	week 4 ,6 ,10	The assessment will be based on a 5-point Likert scale detailed in Table 5 where 0 represents dissatisfied and 4 represents very satisfied.
Subject Discomfort Evaluation	Following the treatments: Baseline,2,3,4,5 weeks	Subject assessment of pain and discomfort associated with treatments using a Pain Visual Analogue Scale (VAS), were 0 is "no pain" and 100 is "intolerable pain.
Subject personal experience	week 10	Subject's likelihood of recommending the treatment or seeking additional treatments recorded in a questionnaire using a six point scale: 1=Extremely Unlikely; 2=Very Unlikely; 3=Somewhat Unlikely; 4=Somewhat likely; 5=Very likely; 6=Extremely likely

Trial Locations

Locations (1)

Knight Dermatology Institute; 🇺🇸 Orlando, Florida, United States